![](https://microbiomeconnectusa.com/sites/default/files/styles/sponsor/public/logos/untitled_design_8_1.png?itok=HiyEMgHk)
Venue
Aloft Boston Seaport District Hotel, 401-403 D Street, Boston, Massachusetts, USA, 02210
Microbiome Connect invites you to join us at the Aloft Boston Seaport District Hotel, November 20-21.
For discounted rooms please click here.
Microbiome Investors
Microbiome Pharma Logo Cloud
Our Trailblazing Speakers
Daniel Cuoto
Chief Operating OfficerVedanta BioNikole Kimes
Chief Executive OfficerSiolta TherapeuticsBharat Dixit
Chief Technology OfficerAdiso TherapeuticsCheri Ackerman
Co-Founder & CEOConcerto BiosciencesBenjamin Hadida
Chief Executive OfficerExeliom BiosciencesMary Poor
Vice President of Quality and CMCSiolta TherapeuticsNik Sharma
Chief Executive OfficerBioCortexVivek Lal
Chief Scientific OfficerAlveolus BioYongkyu Kim
CEOBiomATZTomas De Wouters
CEOPharmaBiomeMatthew Cheng
CEOKanvasBioTravis Whitfill
Co-Founder and Chief Scientific OfficerAzitraTravis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.
His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States.
Christian Freguia
Vice President of ResearchRise TherapeuticsSanjay Jain
Vice President of DevelopmentDermbiontJason Goldsmith
Senior Director of Medical and Analytical ScienceSeresClaudio Cantabrana
Co-founder and CEOMicroviable TherapeuticsRicardo Valladares
CSOSiolta TherapeuticsMallory Gandhi
CTOHollisonPaul Carlson
Principal InvestigatorFDAAlicia Sztretta
Senior Director CMCVedanta BioAmanda Bukardt
Chief Executive OfficerPhiogenChrysi Sergaki
Microbiome Group LeaderMHRASanjay Jain
Vice President of DevelopmentDermbiontTomas De Wouters
CEOPharmaBiomeDenise Kelly
ConsultantSeventureElran Haber, PhD
Chief Executive OfficerBiomicaChris Johnson
Director of ManufacturingAOBiomeRosa Del Campo
Research head - Hospital Romon y CajalGovernment of Spain AdvisorDylan Lawrence
Senior ScientistPfizerJohn Deaton
Vice PresidentR&D ADM
Commercial, Collaboration and Investment Speakers
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/moreno_perugini.jpg?itok=e_Y1hCR-&c=6dba7b88948980fbbbcf03bfaa1af0ab)
Moreno Perugini
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/daniel_couto.jpg?itok=kITR7ASk&c=d0d8769bab2a057fb7f48d3c3e930d9b)
Daniel Cuoto
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/elran_haber_phd.jpg?itok=AK8uIT6q&c=c19342ce317dbfd1061727f3176999f6)
Elran Haber, PhD
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/jacqueline_0.jpg?itok=bCEUr28i&c=c67a23d3de3c9dd444de36834ad13885)
Jacquelin Gaulin
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/paul_moayyedi.jpg?itok=aQSb6ozA&c=6dba7b88948980fbbbcf03bfaa1af0ab)
Paul Moayyedi
Therapeutic and R&D Speakers
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/nikole_kimes.jpg?itok=yqk_fsXD&c=a5470518b08f4c3c3b4ec74a35275407)
Nikole Kimes
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/benjamin_hadida_ceo_exeliom.jpg?itok=h5e87y5e&c=298b6a182ccd20df1eea6197d03f7cc6)
Benjamin Hadida
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/peter_nara_-_keystone.jpg?itok=G3imQVan&c=7b2455ca65d199b5cba98f3699a7ff46)
Peter Nara
Dr. Nara is currently on of the co-founders, the Chief Scientific Officer and President Business Development for Keystone Bio Inc. in St. Louis, Mo., a Systemic-Oral Health Biomedical company that is targeting precision microbiome bio-therapeutics for the elimination of a specific oral bacterial associated with systemic inflammation. He is also the former co-founder, President, Chairman and CEO (1997-2017)and now Chairman Emeritus at Biological Mimetics, Inc. and cofounder of Lantern Pharma Inc. He holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine 2014, and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer. More importantly he and his team are interested developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents.
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/lital_gilad-shaoulian_ceo_founder_purposebio_1.jpg?itok=LqUBiqgP&c=6d02076a597d3a7eba01f9cca6184a04)
Lital Gilad-Shaoulian
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/cheri_ackerman_ceo_concerto_biosciences.png?itok=_PP0b-uz&c=a1936dcfd0bb922ec467a6bb8b5170a9)
Cheri Ackerman
Data Strategy Speakers
![](https://microbiomeconnectusa.com/sites/default/files/styles/panopoly_image_square/public/speakers/oliver_weisser.jpg?itok=XCo9BIoz&c=47c7ae354859320d3a384182015f4206)
Oliver Weisser
Pre-Event Workshops
Pre-Event Workshops
Limited spaces are available for our Pre-Event Workshops, allowing for more in-depth discussion around 2 key themes:
- Women’s Health & the Microbiome
- Streamlining the Regulatory Process to Decrease Time to Market
Networking Zone
Our Networking Zone is the place to be to have partnering meetings, find your next technology, and catch up with your peers over a coffee or lunch. We’ve built more networking time than ever before into the programme this year, giving you plenty of time to catch up with old faces and make the connections you need to fast-track your research.
“A great platform to discuss the currently most relevant microbiome topics – a must for microbiome drug developers” PharmaBiome
Microbiome Connect: USA will return to Boston, November 20-21 2024.
View the Event Schedule
Daniel Cuoto
Chief Operating OfficerVedanta BioNikole Kimes
Chief Executive OfficerSiolta TherapeuticsBharat Dixit
Chief Technology OfficerAdiso TherapeuticsCheri Ackerman
Co-Founder & CEOConcerto BiosciencesBenjamin Hadida
Chief Executive OfficerExeliom BiosciencesMary Poor
Vice President of Quality and CMCSiolta TherapeuticsNik Sharma
Chief Executive OfficerBioCortexVivek Lal
Chief Scientific OfficerAlveolus BioYongkyu Kim
CEOBiomATZTomas De Wouters
CEOPharmaBiomeMatthew Cheng
CEOKanvasBioTravis Whitfill
Co-Founder and Chief Scientific OfficerAzitraTravis Whitfill is an Associate Research Scientist in the Department of Pediatrics. His background began in molecular biology and biochemistry, after receiving scientific training at the MD Anderson Cancer Center and Duke University. He is the co-founder of several additional startup companies, including a Connecticut-based microbiome company, Azitra Inc. He brings strong background in entrepreneurship and business, and is also a partner in a venture capital fund, Bios Partners, bringing experience in public markets, drug development, and venture capital investments.
His research interests are in pediatric emergency medicine and health policy and to improve pediatric acute care across the United States.
Christian Freguia
Vice President of ResearchRise TherapeuticsSanjay Jain
Vice President of DevelopmentDermbiontJason Goldsmith
Senior Director of Medical and Analytical ScienceSeresClaudio Cantabrana
Co-founder and CEOMicroviable TherapeuticsRicardo Valladares
CSOSiolta TherapeuticsMallory Gandhi
CTOHollisonPaul Carlson
Principal InvestigatorFDAAlicia Sztretta
Senior Director CMCVedanta BioAmanda Bukardt
Chief Executive OfficerPhiogenChrysi Sergaki
Microbiome Group LeaderMHRASanjay Jain
Vice President of DevelopmentDermbiontTomas De Wouters
CEOPharmaBiomeDenise Kelly
ConsultantSeventureElran Haber, PhD
Chief Executive OfficerBiomicaChris Johnson
Director of ManufacturingAOBiomeRosa Del Campo
Research head - Hospital Romon y CajalGovernment of Spain AdvisorDylan Lawrence
Senior ScientistPfizerJohn Deaton
Vice PresidentR&D ADM
Partnering
Microbiome Connect was founded on connections – on bringing together the breadth of the microbiome ecosystem to make partnerships that will facilitate industry growth. For 2023, we’re bringing a revamped 1-2-1 Partnering Platform allowing all attendees to meet new people, discover new organizations and create incredible new opportunities.
With our Partnering Platform, you’ll have access to efficient networking and collaboration across every use case – from connecting efficiently with new & familiar faces and meeting potential customers & partners, through to raising capital and recruitment.
How can I get involved?
Our Partnering Platform is open to all conference attendees at no additional cost and is the best way to meet everyone you want to meet at Microbiome Connect. To participate, just get your ticket and complete your profile to let other attendees know about you and your organization’s goals. Two days out from the event, you’ll then be able to review hundreds of profiles and select who you want to meet, with the option to filter attendees by therapeutic area, stage of research, and partnering goals. Then, simply join your meetings on-site – it’s as simple as that.
Want to get the most out of the conference?
Take your conference experience to the next level and maximize your ROI through our tailored sponsorship packages. Get in touch with Simon Pickles, Senior Commercial Partnerships Manager, [email protected] to explore how you can meet your company goals at Microbiome Connect.